title: Maintenance of cAMP in non-heart-beating donor lungs reduces ischemia-reperfusion injury.
abstract: Studies suggest that pulmonary vascular ischemia-reperfusion injury (IRI) can be attenuated by increasing intracellular cAMP concentrations. The purpose of this study was to determine the effect of IRI on capillary permeability, assessed by capillary filtration coeficient (Kfc), in lungs retrieved from non-heart-beating donors (NHBDs) and reperfused with the addition of the beta(2)-adrenergic receptor agonist isoproterenol (iso), and rolipram (roli), a phosphodiesterase (type IV) inhibitor. Using an in situ isolated perfused lung model, lungs were retrieved from NHBD rats at varying intervals after death and either ventilated with O(2) or not ventilated. The lungs were reperfused with Earle's solution with or without a combination of iso (10 microM) and roli (2 microM). Kfc, lung viability, and pulmonary hemodynamics were measured. Lung tissue levels of adenine nucleotides and cAMP were measured by HPLC. Combined iso and roli (iso/roli) reperfusion decreased Kfc significantly (p < 0.05) compared with non-iso/roli-reperfused groups after 2 h of postmortem ischemia. Total adenine nucleotide (TAN) levels correlated with Kfc in non-iso/roli-reperfused (r = 0.89) and iso/roli-reperfused (r = 0.97) lungs. cAMP levels correlated with Kfc (r = 0.93) in iso/roli-reperfused lungs. Pharmacologic augmentation of tissue TAN and cAMP levels might ameliorate the increased capillary permeability observed in lungs retrieved from NHBDs.
authors.affiliation: Division of Cardiothoracic Surgery, Department of Surgery, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
authors.forename: S C
authors.initials: SC
authors.lastname: Hoffmann
authors.forename: M S
authors.initials: MS
authors.lastname: Bleiweis
authors.forename: D R
authors.initials: DR
authors.lastname: Jones
authors.forename: H C
authors.initials: HC
authors.lastname: Paik
authors.forename: P
authors.initials: P
authors.lastname: Ciriaco
authors.forename: T M
authors.initials: TM
authors.lastname: Egan
mesh_terms: D000227:Adenine Nucleotides / Q000378:metabolism; D000318:Adrenergic beta-Agonists / Q000008:administration & dosage / Q000494:pharmacology; D000818:Animals; D001794:Blood Pressure; D002102:Cadaver; D002199:Capillary Permeability; D002470:Cell Survival; D002851:Chromatography, High Pressure Liquid; D000242:Cyclic AMP / Q000378:metabolism*; D007545:Isoproterenol / Q000008:administration & dosage / Q000494:pharmacology; D008168:Lung / Q000378:metabolism* / Q000473:pathology; D016040:Lung Transplantation; D008297:Male; D010100:Oxygen / Q000008:administration & dosage; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology; D011652:Pulmonary Circulation; D051381:Rats; D017207:Rats, Sprague-Dawley; D015424:Reperfusion; D015427:Reperfusion Injury / Q000473:pathology / Q000517:prevention & control*; D020889:Rolipram / Q000494:pharmacology; D014019:Tissue Donors
chemical_list: D000227:Adenine Nucleotides; D000318:Adrenergic beta-Agonists; D010726:Phosphodiesterase Inhibitors; D000242:Cyclic AMP; D020889:Rolipram; D007545:Isoproterenol; D010100:Oxygen